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Abstract
Purpose—Drug treatment can be effective in community-based settings, but drug users tend to
under-utilize these treatment options and instead seek services in emergency departments (ED)
and other acute care settings. The goals of this study were to describe prevalence and correlates of
drug-related ED visits.
Basic procedures—This study used data from the National Epidemiologic Survey on Alcohol
and Related Conditions (NESARC), which is a nationally representative survey of 43,093 U.S.
residents.
Main findings—The overall prevalence of drug-related ED visits among lifetime drug users was
1.8%; for those with a lifetime drug use disorder, 3.7%. Persons with heroin dependence and
inhalant dependence had the highest rates of ED visits, and marijuana dependence was associated
with the lowest rates. Multivariate analyses revealed that being socially connected (i.e., marital
status) were protective factors against ED visits, whereas psychopathology (i.e., personality or
mood disorders) were risk factors.
Conclusions—Significant variability exists for risk of ED use for different types of drugs.
These findings can help inform where links between EDs with local treatment programs can be
formed to provide preventative care and injury-prevention interventions to reduce the risk of
subsequent ED visits.
Drug use and abuse is a major public health problem that can lead to serious health
consequences, criminal involvement, employment problems, strained relationships,
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homelessness, poor treatment compliance and outcomes, and lower quality of life.
1–5 Drug treatment can be effective in community-based settings, but drug users
tend to under-utilize these treatment options and instead seek services in emergency
departments (ED) and other acute care settings.6–9 These settings are often the
most expensive and least effective way of addressing drug problems. Research on
substance use disorders consistently demonstrates that drug problems often require
treatment over the course of several months.10 Recent research also shows that
drug-related ED usage is increasing,11 resulting in billions of dollars in costs to the
public health care system.12–17 The costs are even higher when other drug-
treatment services and criminal justice expenditures are considered.18
Importance
Research on the burden of alcohol and associated ED and acute care service use is well
developed, but little is known about drug-related burden and associations. Increasing this
body of research is necessary given evidence suggesting that the consequences of drug use
on ED and primary care service settings may be greater than those of alcohol use alone.17, 19
This research is needed to ensure that supportive policies are implemented and funding
delivered to treat these chronic conditions in community-based settings.20 This research can
also contribute to the development of effective and efficient assessments and brief
interventions appropriate for ED and acute care settings.21 Finally, identifying repeat ED
and acute care service users, and describing their clinical and psychosocial profiles, can lead
to targeted approaches for treatment of persons who have the greatest impact on the health
care system.20 Leading experts in alcohol and drug treatment services recommend using
population-based surveys to understand the burden placed by substance misuse on the
general health care system and characteristics of substance-related service users.19, 21
Goal of This Investigation—The goal of this investigation was to gain a better
understanding of drug-related ED visits using nationally representative data. Specifically,
this study sought to 1) describe sociodemographic patterns and correlates of drug-related ED
visits, and 2) examine prevalence of drug-related ED visits for different types of drug use
and drug use disorders.
Methods
Subjects, Sampling, and Interviews
This study used data from the National Epidemiologic Survey on Alcohol and Related
Conditions (NESARC), which is a nationally representative survey of 43,093 non-
institutionalized U.S. residents aged 18 years and older.22 The NESARC was based on a
multistage sampling design, oversampling young adults, Hispanics, and Blacks to obtain
reliable statistical estimation in these subpopulations, and to ensure appropriate
representation of racial/ethnic groups. The overall response rate was 81%. Data were
weighted at the individual and household levels and to adjust for oversampling and non-
response on select demographic variables. Data were also adjusted to be representative of
the U.S. population as assessed during the 2000 census.
In the administration of this survey, U.S. Census Bureau workers, trained by National
Institute on Alcohol Abuse and Alcoholism (NIAAA) staff, administered the Alcohol Use
Disorders and Associated Disabilities Interview Schedule – DSM-IV version (AUDADIS-
IV). AUDADIS-IV is a structured interview designed for administration by trained lay
interviewers. AUDADIS-IV assesses 10 Diagnostic and Satistical Manual of Mental
Disorders-4th Edition (APA, 2000) substance use disorders and has evidenced good-to-
excellent reliability for the assessment of substance use disorders.23, 24 Descriptions of the
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NESARC survey, sampling protocol, and related publications are described in detail in prior
studies.22–24 These data are publicly available and all identifying information have been
removed. This secondary data analysis met exemption from IRB approval.
Measurement
Drug use and drug use disorders—In this study, drug use refers to any lifetime
history of any non-nicotine drug for purposes of getting high, including amphetamines,
sedatives, tranquilizers, opioids, cannabis, cocaine and crack, hallucinogen, inhalants,
heroin, and other drugs. Drug use disorder (DUD) refers to meeting DSM-IV criteria for
either drug abuse or drug dependence for any of the aforementioned drug types.
Drug treatment and ED service utilization—Participants were asked to reply yes or
no to the questions: “Have you ever gone anywhere or seen anyone for a reason that was
related in any way to your use of medicines or drugs – a physician, counselor, Narcotics
Anonymous, or any other community agency or professional?” Participants who endorsed
this question were then asked whether they used any of 14 different treatment services, such
as 12-step, clergy, outpatient, and inpatient (the full set of services are summarized in Table
3). Use of emergency department services was based on the question, “In your entire life,
did you ever go to an emergency room for any reason related to your drug use” (yes/no).
Sociodemographic variables—Several sociodemographic and clinical variables were
assessed in this study: racial/ethnic groups including Whites (non-Hispanic), Blacks, and
Hispanics, gender (male, female), living area (urban, rural), marital status (married,
separated, never married), annual personal income (in dollars), age (in years), and
employment status (employed, unemployed). Insurance status referred to current private or
public insurance at the time of interviewing (e.g.., Medicare, Medicaid, CHAMPUS,
CHAMPVA, VA or other military healthcare). Data regarding insurance status at time of
diagnosis or when treatment was sought is not available in the NESARC data set.
Clinical variables—Five clinical variables were included in this study: lifetime history of
a DSM-IV alcohol use disorder (i.e., abuse or dependence), lifetime history of an anxiety
disorder (i.e., social phobia, panic disorder with or without agoraphobia, and generalized
anxiety disorder), and lifetime history of a mood disorder (i.e., major depression, bipolar
disorder, dysthmia, cyclothymia), personality disorder (i.e., antisocial, avoidant, dependent,
obsessive-compulsive, paranoid, schizoid, and histrionic), and polydrug use disorder (i.e.,
having a lifetime history of more than three non-nicotine or non-caffeine DSM-IV drug use
disorders). Note that this definition of polydrug use disorder differs from that of
polysubstance-related disorder as defined in DSM-IV (p. 293). Last, it is necessary to note
that when assessed for anxiety disorder-related symptoms, participants were not assessed for
PTSD-related symptoms.
Analytic plan
Analyses were computed using SUDAAN Version 9.0.25 This system implements a Taylor
series linearization to adjust standard errors of estimates for complex survey sampling
design effects including clustered data. Chi-square tests were used to make bivariate
comparisons of study variables. Multivariate logistic regression analyses were used to
examine service utilization and barriers among racial and ethnic groups, while adjusting for
other sociodemographic and clinical variables. These covariates were selected based on
theoretical plausibility and prior empirical findings.
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Characteristics of drug-related ED service users
Approximately 21.2% of persons in the NESARC survey reported a lifetime history of drug
use, and 9.4% of the sample met lifetime criteria for a drug use disorder (abuse or
dependence; excludes alcohol and nicotine). Chi-squared tests were used to identify
associations between drug-related ED visits and other sociodemographic and clinical
variables. Analyses were conducted separately for persons with lifetime drug use and a
lifetime drug use disorder. The overall prevalence of drug-related ED visits among lifetime
drug users was 1.8%; for those with a lifetime drug use disorder, 3.7%.
As summarized in Table 1, among persons with lifetime drug use, the prevalence of having
lower educational attainment, being not currently married, and having lower income was
higher among those with at least one drug-related ED visit than those without an drug-
related ED visits. Among persons with a lifetime drug use disorder, the prevalence of having
at being currently not married and having a low income was higher among those who had at
least one drug-related ED visit than those who had not.
ED use by drug type
In order to examine how the percentage of persons with a drug-related ED visit differs for
each drug, the weighted percentage of users who had a drug-related ED visit was estimated
separately for each type of drug examined. These percentages, as well as unweighted sample
sizes are presented in Table 2. While heroin was the least commonly used drug, persons who
had ever used heroin had a high percentage of drug-related ED visits (18.54%, SE = 3.66).
In contrast, marijuana was by far the most commonly used drug, but individuals who used
marijuana had a low prevalence of drug-related ED visits (1.71%, SE = 0.16). For all
remaining drug types, the prevalence of drug-related ED visit among people who had used
that drug ranged between 3.92% and 6.33%.
Among persons with a drug use disorder, the results were similar to those of persons who
had ever used a drug. Individuals with a heroin use disorder had the highest prevalence of
drug-related ED use (26.83% SE= 5.17), and individuals with a marijuana use disorder had
the lowest (3.05% SE= .34). Persons with other drug use disorders had a prevalence of ED
use between 7.53% and 16.02%, depending on the drug. Although not formally tested, ED
visits appeared to be more common for each drug examined among those who met criteria
for a disorder than the larger group of persons who reported lifetime use (with or without a
disorder).
Differences in service use
The prevalence of other drug-related service use among individuals who have and have not
had a drug-related ED visit was also examined among individuals with a drug use disorder
(Table 3). Across all types of services assessed, individuals who have had a drug-related ED
visit were more likely to report also having used other services. The most frequently used
services among individuals who have had an ED visit were “narcotics/alcoholics anonymous
or any 12 step meeting” (67.0%) and private professionals, including psychiatrics,
psychologists, social workers, and others (68.3%).
Factors associated with one or more drug-related ED visits
Logistic regression was used to further examine the relationship between drug-related ED
visits and several demographic and mental health variables, as well as number of lifetime
drug use disorders, alcohol use disorder, and service use, among individuals with a drug use
disorder. Table 4 reports the odds ratio and 95% confidence interval for each independent
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variable used in the multivariate regression analysis. The odds of having a drug-related ER
visit for persons with a drug use disorder who had been widowed, divorced or separated was
1.8 times the odds compared to persons who were married (OR =1.81, 95% C.I. = 1.04–
3.15). Having a mood disorder increased the likelihood of a drug-related ED visit by 1.79
times among persons with a drug use disorder (95% C.I. = 1.07–3.00). Similarly, the odds of
having a drug-related ED visit for persons with a personality disorder were 1.6 times the
odds compared to persons without a personality disorder (95% C.I. = 1.03–2.48). Age,
gender, race, education, number of drug use disorders, alcohol use disorder, and anxiety
disorder were not significant correlates of having a drug-related ED visit.
Discussion
To date, this is the first study that has used nationally representative data to examine patterns
and correlates of drug-related ED visits. This study overcomes challenges of limited
generalizability and regional variability that are common to clinic-based surveys. A
particularly important feature of this study is the focus on drug-related ED visits across
different classes of drugs, which enables a better understanding of the service consequences
of different drug types. This is particularly important for tailoring interventions and targeting
services.
The overall prevalence of drug-related ED use among persons with lifetime drug use and
those with a lifetime drug use disorder was low. However, disaggregating the prevalence by
types of drugs of abuse revealed that the prevalence is driven downward by the high
prevalence of marijuana use and disorders but low ED use for that particular substance.
However, drugs such as heroin, inhalants, and “other drugs,” were less commonly used but
associated with significantly higher rates of ED use for individuals who use marijuana.
Thus, the low overall rate can be attributed to the large number of marijuana users and those
with a marijuana use disorder and the relatively low risk of ED visits for this drug. This
finding indicates that ED clinicians see a disproportionate number of individuals who use
substances such as heroin, inhalants, and “other drugs,” and may be uniquely well-position
to provide drug-related interventions and make referrals to drug treatment specifically for
these substances.
Interestingly the prevalence of ED use among lifetime users of heroin and “other drugs”
(18.5% and 12.3%, respectively) approached the same rate of ED use among those with a
parallel lifetime drug use disorder (26.8% and 14.5%). For other drugs, the prevalence of
ED use twice as prevalent among persons with substance use disorder compared to persons
who reported lifetime use only. This demonstrates the substantial consequences of heroin
use and abuse on the health care system, underscoring the need for intervention among those
with and without a heroin use disorder. The types of drugs included in the “other drug use”
category were not available in the data set. However, results suggest the importance of doing
a wide range of assessments for specific types of drug use as opposed to only major classes
of drugs.
The high prevalence of ED use among persons with an inhalant use disorder is also
particularly notable. Inhalant use disorders were associated with a high prevalence of ED
visits, second only to heroin. Inhalants are among the most common and dangerous of all
types of psychoactive substances but the least studied,26 and few studies exist on patterns of
service use among this group. These findings indicate the need for future work on inhalant
use disorders and emergency service utilization. While these findings further confirm the
significant consequences of inhalant use and the need for prevention, it is also important to
consider that inhalants are an indicator of multiple psychiatric and substance use
comorbidities,27, 28 which could be the underlying factors for ED use. ED facilities may be
Perron et al. Page 5













particularly well-positioned to reach out to inhalant users who are otherwise missed through
current outreach efforts, and to engage in research with this understudied population.
Some psychosocial and clinical factors also emerged in the multivariate analysis.
Specifically, being socially connected (i.e., marital status) were protective factors against
ED visits, whereas psychopathology (i.e., personality or mood disorder) were risk factors.
These findings are consistent with other research on drug use disorders and their functional
impacts. Future research should consider the direction of effects and effect sizes in
disaggregated analyses. It was beyond the scope of the current study to examine the different
multivariate associations due to low cell counts and the risk of committing a Type II error.
However, this study provides the basic framework for a disaggregated approach to facilitate
analysis of specific drug types with adequate sample sizes.
Regarding service utilization, persons who reported an ED use were likely to have also
reported lifetime use of other services. It is possible that referrals for other services were
received from the ED. However, the limitations of the existing data do not allow us to
determine pathways or temporal ordering of service use. Other services used could be a
response to the ED treatment (e.g., inpatient treatment) or part of the pathway (e.g., crisis
center). However, these data can be used to help inform where links between EDs with local
treatment programs can be formed to provide preventative care and injury-prevention
interventions to reduce the risk of subsequent ED visits.
Study Limitations
The findings should be considered in the context of the study limitations. For example, data
are not available on the number of drug-related ED visits, which is necessary for
understanding the differential risks of different types of drug use. While this study
considered the role of other drug use disorders regarding ED visits, the study could not
effectively address possible complex interactions between different types of drugs and
resultant ED visits. The specific reasons for ED visits were not available in this data set.
Although the survey clearly queried respondents about specific drug-related ED visits, the
nature of the injuries and type of medical attention sought would be particularly informative.
Finally, the NESARC was not designed to provide information on whether or not an
intervention provided in the ED was effective in reducing drug use, accessing treatment
services, or preventing future ED use.
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Table 2
Prevalence of drug-related emergency department visits by type of drug use and lifetime drug use disorder
Drug type N Drug-related ED Visit % (95% CI)
Amphetamine use 1,750 4.5 (3.6–5.7)
Amphetamine use disorder 765 7.9 (6.1–10.3)
Sedative use 1,609 5.3 (4.2–6.8)
Sedative disorder 402 11.3 (8.4–14.9)
Tranquilizer use 1,301 6.3 (4.9–8.1)
Tranquilizer use disorder 372 13.1 (10.0–16.9)
Opioid use 1,815 5.2 (4.2–6.6)
Opioid use disorder 521 10.5 (7.9–13.8)
Cannabis use 8,172 1.7 (1.4–2.1)
Cannabis use disorder 3,297 3.1 (2.4–3.8)
Cocaine/crack use 2,528 4.2 (3.3–5.2)
Cocaine/crack use disorder 1,159 7.6 (6.0–9.6)
Hallucinogen use 2,176 3.9 (3.1–4.9)
Hallucinogen use disorder 623 7.5 (5.7–9.8)
Inhalant use 664 6.2 (4.4–8.8)
Inhalant use disorder 138 16.0 (10.4–23.9)
Heroin use 150 18.5 (12.3–26.9)
Heroin use disorder 104 26.8 (17.8–38.3)
Other drug use 87 12.3 (6.5–22.0)
Other drug use disorder 39 14.5 (5.9–31.3)
Note: All drug use disorders based on DSM-IV criteria. CI = Confidence Interval.
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Table 3
Drug-related service use among individuals with and without a drug-related emergency department visit
among persons with a lifetime drug use disorder
Service Type ED visit (%) No ED visit (%) χ2, p-value
NA/AA/12 Step 67.0 59.2 4.5, 0.04
Family/Social Services 36.0 17.3 11.1, 0.001
Detoxification 56.3 33.2 15.7, < 0.001
Inpatient 59.2 22.5 40.9, < 0.001
Outpatient/Partial Hospitalization 49.4 32.2 10.5, 0.002
Rehabilitation 61.7 47.6 7.1, 0.01
Methadone Maintenance 10.6 3.6 6.7, 0.02
Halfway House 24.5 8.1 15.4, < 0.001
Crisis Center 15.5 3.5 12.6, < 0.001
Employee Assistance Program 15.2 7.8 3.3, 0.08
Clergy/Priest/Rabbi 29.3 17.7 6.0, 0.02
Private Professional 68.3 51.1 9.0, 0.004
Other 23.3 8.8 13.3, < 0.001
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Table 4
Multivariate association between service use and drug-related emergency department visits among persons
with a drug use disorder.
Odds Ratio 95% CI
Sex: Male 0.98 (0.60–1.61)
Education (less than H.S. is reference)
 H.S./G.E.D. 0.96 (0.50–1.86)
 Some College or greater 0.91 (0.46–1.79)
Marital Status (Never Married is reference)
 Married 0.80 (0.42–1.52)
 Widowed/Divorced/Separated 1.81 (1.04–3.15)
Household Income (≥ $70,000 is reference)
 $0–$19,999 1.06 (0.47–2.42)
 $20,000–$34,999 1.10 (0.50–2.44)
 $35,000–$69,999 0.57 (0.25–1.27)
Number of Drugs Disorders (1 is reference)
 2 1.00 (0.34–2.91)
 3 or more 2.21 (0.86–5.69)
Alcohol Use Disorder 0.54 (0.25–1.18)
Mood Disorder 1.79 (1.07–2.00)
Any Personality Disorder 1.60 (1.03–2.48)
Any Service Use 2.12 (0.56–8.01)
Note: Values in bold are statistically significant based on an odds ratio that does not bound 1.0.
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